WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.250.73'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

LOBEF – Shroom Investor πŸ„

LOBEF

Lobe Sciences Ltd.

35 views6 min read

Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

Lobe Sciences
Dosing In Human Clinical Trial To Commence Within WeeksVancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its e... Read More...
857 views4 min read

Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,... Read More...
862 views6 min read

Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible n... Read More...
1271 views4 min read

Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other init... Read More...
123 views4 min read

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Lobe Sciences
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENΕ« Pty Ltd... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!